Collectively, our study uncovers the oncogenic functions of RRM2 in ATRT cell lines, and highlights the therapeutic potential of targeting RRM2 in ATRT. The promising effect of COH29 on ATRT suggests its potential suitability for clinical trials as a novel therapeutic approach for ATRT.

5 months ago

Journal

RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)

COH29

6ms

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment. (PubMed, Cell Biosci)

Our findings suggest that RRM2 regulates docetaxel resistance in prostate cancer by stabilizing ANXA1-mediated activation of the PI3K/AKT pathway. Targeting RRM2 or ANXA1 may offer a promising therapeutic strategy to overcome docetaxel resistance in prostate cancer.

6 months ago

Journal

ANXA1 (Annexin A1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)

AKT1 overexpression • ANXA1 overexpression • ANXA1 expression

docetaxel • COH29

1year

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists (clinicaltrials.gov)

P1, N=12, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting | N=19 --> 12 | Trial completion date: Dec 2022 --> Dec 2023

1 year ago

Enrollment closed • Enrollment change • Trial completion date

H2AX (H2A.X Variant Histone)

COH29